June 17, 2026
In a new byline for MedCity News, Pleio CEO Michael Oleksiw argues that healthcare’s rush to automate patient engagement is outpacing the trust patients actually have in AI-led care. Drawing a parallel to Waymo’s Senate testimony on remote human operators, Oleksiw makes the case that fear, isolation, and eroded trust — not logistics — are the real drivers of medication nonadherence, and that no amount of automation can substitute for sustained human connection. The piece outlines what healthcare leaders should demand from AI vendors before they automate away the touchpoints that actually keep patients engaged.
June 5, 2026
Asembia 2026 brought the specialty pharmacy world together and the conversations are still resonating. Pleio CEO Michael Oleksiw and Chief Experience Officer Abby Reynolds, PharmD sat down with the Pharmacy Podcast Network for their annual Asembia Rewind, alongside leaders from across the specialty ecosystem. Tune in to hear their perspective on the future of patient engagement and why human connection remains at the heart of what Pleio does.
May 18, 2026
Pharma has invested heavily in bringing therapy closer to patients. But from the vantage point of the pharmacy counter, something critical is missing. Pleio’s Chief Pharmacy Officer Mark Gregory writes for MM&M on the emotional barriers DTP programs consistently overlook, and what it takes to build patient support that actually works. Mark makes the case that as DTP models expand and the medication journey becomes increasingly decentralized, pharmacist insight into how patients experience and discontinue therapy should shape program design from the start.
April 27, 2026
In an interview with Pharmacy Times at Asembia’s AXS26 Summit, Michael Oleksiw, CEO of Pleio addressed the challenge of medication nonadherence in specialty therapy, where nearly half of all treatment failures are tied to adherence issues. Mechanical interventions like push notifications alone fall short; overcoming nonadherence in specialty therapies requires AI-driven insights paired with human-centered outreach to tackle the emotional and psychological barriers patients face. Oleksiw highlighted GLP-1 medications as a prime example, where stigma, dose escalation, and recurring emotional hurdles make specialty therapy adherence especially difficult to sustain.
April 2, 2026
In part two of his Pharmaceutical Commerce interview series, Pleio CEO Michael Oleksiw reframes pharma’s adherence problem as fundamentally human — not logistical. From the industry’s persistent “one-and-done” challenge to the underestimated role of loneliness in early discontinuation, Oleksiw makes the case that lasting behavior change requires meeting patients emotionally before overwhelming them with tools, reminders, or information they aren’t yet ready to act on.
April 1, 2026
In his Pharma Live byline, Pleio CEO Michael Oleksiw puts empathetic AI to the test starting with a direct question to ChatGPT. The answer cuts to the heart of what the industry needs to hear: AI can simulate empathy, but it can’t feel it. In healthcare, where trust, emotional presence, and human judgment determine whether patients stay on therapy, that distinction isn’t semantic, it’s consequential.
FOR MEDIA INQUIRIES PLEASE EMAIL media@pleio.com.